Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021671 · ClinicalTrials.gov registry record · Phase 3
Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 3,720
- Enrollment target
NCT00021671 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 3,720 participants.
The verdict
NCT00021671, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,720 participants
- Enrollment target
Study Summary
The purpose of this study is to see if antibiotic drugs given to treat an infection of the uterus during pregnancy can reduce the chances of HIV being passed from an HIV-positive mother to her baby. A link between bacterial disease of the vagina, premature birth, infection of the uterus during pregnancy, and the passing of HIV from a mother to her baby has been found. Early treatment of these problems may reduce the risk of passing HIV from an HIV-positive mother to her baby. \[Note: As of 02/21/03, enrollment into this study was halted because preliminary data showed that the study antibiotics were not effective in preventing mother-to-child HIV transmission.\]
Interventions
- DRUG Metronidazole
- DRUG Erythromycin
- DRUG Nevirapine
- DRUG Ampicillin sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,720 participants |
| Est. Completion | 2004-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00021671
The ClinicalTrials.gov registry entry for NCT00021671 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,720 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Metronidazole is the first listed.
NCT00021671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00021671 about?
NCT00021671 is a clinical study titled "Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission". The purpose of this study is to see if antibiotic drugs given to treat an infection of the uterus during pregnancy can reduce the chances of HIV being passed from an HIV-positive mother to her baby. A link between bacterial disease of the vagina, premature birth, infection of the uterus during preg...
What is the current status of trial NCT00021671?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,720 participants. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00021671?
The interventions under investigation include: Metronidazole (DRUG), Erythromycin (DRUG), Nevirapine (DRUG), Ampicillin sodium (DRUG).
Who is sponsoring clinical trial NCT00021671?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.